|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...2930313233343536373839...6566» |
- |||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion, Enrollment change, Trial primary completion date: Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines (clinicaltrials.gov) - Nov 14, 2014
P4, N=538, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | N=3000 --> 538 | Trial primary completion date: Dec 2015 --> Dec 2013
- ||| ExPEC-4V / J&J, GSK
New P1 trial: Vaccine Against Escherichia Coli Infection (clinicaltrials.gov) - Nov 13, 2014
P1, N=194, Active, not recruiting, Sponsor: GlycoVaxyn AG
- Trial completion, Enrollment change: Iron Homoeostasis in Inflammation (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=472, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Completed | N=3000 --> 538 | Trial primary completion date: Dec 2015 --> Dec 2013 Recruiting --> Completed | N=1500 --> 472
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Phase classification, Trial initiation date: Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease (clinicaltrials.gov) - Nov 12, 2014
P4, N=1, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed | N=1500 --> 472 Phase classification: P=N/A --> P4 | Initiation date: Jun 2010 --> Sep 2010
- FDG PET: TEPvENDO: 18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=150, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment status, Phase classification, Trial initiation date: Post Market Surveillance to Observe Safety of Prevenar13™ in Adults (clinicaltrials.gov) - Nov 12, 2014
P4, N=600, Enrolling by invitation, Sponsor: Pfizer
Phase classification: P=N/A --> P4 | Initiation date: Jun 2010 --> Sep 2010 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 | Initiation date: Apr 2013 --> Dec 2013
- |||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion, Enrollment change: Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine (clinicaltrials.gov) - Nov 12, 2014
P4, N=62626, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 | Initiation date: Apr 2013 --> Dec 2013 Active, not recruiting --> Completed | N=20000 --> 62626
- Enrollment closed: Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis (clinicaltrials.gov) - Nov 12, 2014
P1, N=12, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed | N=20000 --> 62626 Recruiting --> Active, not recruiting
- clindamycin phosphate / Generic mfg.
Trial completion, Trial primary completion date: Treatment of Bacterial Vaginosis Combined With Human Lactobacilli (clinicaltrials.gov) - Nov 11, 2014
P4, N=75, Completed, Sponsor: Skaraborg Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Oct 2014
- ||||| MenABCWY vaccine (GSK3536819A) / GSK
New P2 trial: Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (clinicaltrials.gov) - Nov 7, 2014
P2, N=240, Not yet recruiting, Sponsor: Novartis Vaccines
- Trial completion, Enrollment change, Trial primary completion date: Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=1554, Completed, Sponsor: Colorado State University
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Oct 2014 Recruiting --> Completed | N=1150 --> 1554 | Trial primary completion date: Dec 2011 --> Apr 2013
- Negaban (temocillin) / Eumedica
New P4 trial, Gram negative: Temocillin Pharmacokinetic in Hemodialysis (clinicaltrials.gov) - Nov 6, 2014
P4, N=16, Active, not recruiting, Sponsor: AZ Sint-Jan AV
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P3 trial: Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children (clinicaltrials.gov) - Nov 6, 2014
P3, N=1660, Completed, Sponsor: Walvax Biotechnology Co., Ltd.
- Trial completion: Alere Mycobacterium Tuberculosis Urine Study (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=60, Completed, Sponsor: Research Center Borstel
Recruiting --> Completed | N=1150 --> 1554 | Trial primary completion date: Dec 2011 --> Apr 2013 Recruiting --> Completed
- meropenem / Generic mfg.
Trial completion, Enrollment change: Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=10, Completed, Sponsor: Oslo University Hospital
Recruiting --> Completed Active, not recruiting --> Completed | N=50 --> 10
- mupirocin / Generic mfg.
New P4 trial: Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) (clinicaltrials.gov) - Nov 6, 2014
P4, N=12, Recruiting, Sponsor: Destiny Pharma Ltd
- Trial completion, Trial primary completion date: Siemens VOC TB Pilot Study (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=60, Completed, Sponsor: Research Center Borstel
Active, not recruiting --> Completed | N=50 --> 10 Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Dec 2013
- Trial primary completion date: Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=76, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Dec 2013 Trial primary completion date: May 2015 --> May 2016
- |||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK, Rotarix (rotavirus vaccine) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial primary completion date: Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants (clinicaltrials.gov) - Nov 5, 2014
P3, N=4003, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Jul 2013 --> Nov 2011
- Trial completion, Enrollment change: How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=206703, Completed, Sponsor: NorthShore University HealthSystem
Trial primary completion date: Jul 2013 --> Nov 2011 Recruiting --> Completed | N=15000 --> 206703
- | exeporfinium chloride (XF-73) / Destiny Pharma
New P1/2 trial: Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=60, Recruiting, Sponsor: Destiny Pharma Ltd
- | doxycycline / Generic mfg.
New P2 trial: Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana (clinicaltrials.gov) - Nov 3, 2014
P2, N=200, Not yet recruiting, Sponsor: Kwame Nkrumah University of Science and Technology
- fosfomycin tromethamine / Generic mfg.
Trial completion: Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol (clinicaltrials.gov) - Nov 3, 2014
P1, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=15000 --> 206703 Recruiting --> Completed
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
New P2/3 trial: Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) - Oct 31, 2014
P2/3, N=28, Recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
- | New P2 trial: A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) (clinicaltrials.gov) - Oct 31, 2014
P2, N=83, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- ceftriaxone / Generic mfg.
Enrollment change, Trial termination: EVOTAR: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients. (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=77, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed N=300 --> 77 | Active, not recruiting --> Terminated; lack of recruitement
- ||||| Enrollment change: Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. (clinicaltrials.gov) - Oct 30, 2014
P3, N=286, Completed, Sponsor: Laboratoires Thea
N=300 --> 77 | Active, not recruiting --> Terminated; lack of recruitement N=222 --> 286
- |||| Nimenrix (MenACWY-TT) / Pfizer
Trial completion: Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers (clinicaltrials.gov) - Oct 30, 2014
P2, N=202, Completed, Sponsor: Novartis Vaccines
N=222 --> 286 Active, not recruiting --> Completed
- Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Nimenrix (MenACWY-TT) / Pfizer
Trial completion, Enrollment change, Trial primary completion date: Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines (clinicaltrials.gov) - Oct 30, 2014
P1/2, N=12, Completed, Sponsor: Leiden University Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Oct 2013 --> Feb 2014
- Trial completion: Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485) (clinicaltrials.gov) - Oct 30, 2014
P2, N=650, Completed, Sponsor: Aeras
Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Oct 2013 --> Feb 2014 Active, not recruiting --> Completed
- Shanchol (oral cholera vaccine) / Sanofi
Trial completion, Trial primary completion date: To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh (clinicaltrials.gov) - Oct 30, 2014
P2, N=330, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2010
- Enrollment closed: Peristeen Bowel Irrigation System in Cauda Equina (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: University of Manitoba
Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2010 Recruiting --> Active, not recruiting
- Trial completion: Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=2900, Completed, Sponsor: PATH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: PIN-UP: Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=30, Terminated, Sponsor: Odense University Hospital
Active, not recruiting --> Completed N=300 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Dec 2013; Study logistics proved difficult and enrollment never moved beyond the pilot phase.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
New P3 trial, Combination therapy, Head-to-Head: REFLATE TB2: Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (clinicaltrials.gov) - Oct 24, 2014
P3, N=460, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Trial completion, IO biomarker: Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers (clinicaltrials.gov) - Oct 24, 2014
P1, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 30 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Dec 2013; Study logistics proved difficult and enrollment never moved beyond the pilot phase. Active, not recruiting --> Completed
- Trial completion, IO biomarker: Multi-Drug Resistant Tuberculosis in Korea (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=2040, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- afabicin oral (Debio 1450) / Debiopharm
Clinical: A Single Dose Study of Debio 1450 in Healthy Subjects (clinicaltrials.gov) - Oct 23, 2014
P1, N=48, Completed, Sponsor: Debiopharm International SA
Recruiting --> Completed Recruiting --> Completed
- Clinical: Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=200, Enrolling by invitation, Sponsor: University of Alabama at Birmingham
- Enrollment closed: MOSAIC: Effect of Raw Milk on the Immune Response Upon Cholera Vaccination (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=42, Active, not recruiting, Sponsor: NIZO Food Research
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Enrollment closed: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (clinicaltrials.gov) - Oct 22, 2014
P2, N=300, Active, not recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and Children (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=87, Active, not recruiting, Sponsor: PATH
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Feb 2015
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial: A P3 Comparator Trial in Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Oct 22, 2014
P3, N=438, Not yet recruiting, Sponsor: Durata Therapeutics, Inc.
- | linezolid oral / Generic mfg.
New P2 trial: ABSSSI: MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection (clinicaltrials.gov) - Oct 22, 2014
P2, N=120, Not yet recruiting, Sponsor: MicuRx
- || Trial primary completion date: Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=700, Not yet recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Feb 2015 Trial primary completion date: May 2015 --> Dec 2015
- || Trial initiation date: Evaluation of Enhanced Syphilis Screening Among HIV-positive Men (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=3131, Not yet recruiting, Sponsor: Ontario HIV Treatment Network
Trial primary completion date: May 2015 --> Dec 2015 Initiation date: Jul 2014 --> Dec 2014
- afabicin IV (Debio 1450 IV) / Debiopharm, afabicin oral (Debio 1450) / Debiopharm
Clinical: A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers (clinicaltrials.gov) - Oct 20, 2014
P1, N=40, Suspended, Sponsor: Debiopharm International SA
Initiation date: Jul 2014 --> Dec 2014 Recruiting --> Suspended
- ||| Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
New P1 trial: Pharmacokinetics and Safety of Solithromycin in Adolescents and Children (clinicaltrials.gov) - Oct 20, 2014
P1, N=64, Not yet recruiting, Sponsor: Cempra Pharmaceuticals
- ||| Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=30000, Not yet recruiting, Sponsor: University of Massachusetts, Worcester
- ||||||| Trial completion: Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents (clinicaltrials.gov) - Oct 17, 2014
P3, N=446, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Suspended Active, not recruiting --> Completed